Ingevity Corporation
NGVT
$59.51
-$0.26-0.44%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.21B | 1.21B | 1.18B | 1.24B | 1.31B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.21B | 1.21B | 1.18B | 1.24B | 1.31B |
| Cost of Revenue | 729.40M | 732.40M | 692.70M | 762.50M | 864.30M |
| Gross Profit | 481.90M | 479.60M | 486.80M | 473.10M | 444.20M |
| SG&A Expenses | 168.90M | 162.70M | 154.70M | 158.80M | 163.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 500.00K | 500.00K |
| Total Operating Expenses | 926.60M | 922.60M | 873.10M | 946.60M | 1.05B |
| Operating Income | 284.70M | 289.40M | 306.40M | 289.00M | 255.80M |
| Income Before Tax | -27.90M | -36.10M | -57.10M | -155.80M | -318.60M |
| Income Tax Expenses | 27.00M | 12.10M | -9.20M | -31.40M | -60.80M |
| Earnings from Continuing Operations | -54.90 | -48.20 | -47.90 | -124.40 | -257.80 |
| Earnings from Discontinued Operations | 2.70M | -154.70M | -154.70M | -154.70M | -154.70M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.90M | -216.60M | -353.80M | -430.30M | -563.70M |
| EBIT | 284.70M | 289.40M | 306.40M | 289.00M | 255.80M |
| EBITDA | 388.70M | 394.00M | 415.10M | 404.80M | 369.60M |
| EPS Basic | -1.80 | -5.95 | -9.74 | -11.85 | -15.53 |
| Normalized Basic EPS | 3.44 | 3.46 | 4.16 | 3.41 | 2.89 |
| EPS Diluted | -1.83 | -5.95 | -9.74 | -11.84 | -15.53 |
| Normalized Diluted EPS | 3.42 | 3.45 | 4.14 | 3.40 | 2.88 |
| Average Basic Shares Outstanding | 145.41M | 145.45M | 145.33M | 145.21M | 145.11M |
| Average Diluted Shares Outstanding | 146.64M | 146.18M | 146.06M | 145.66M | 145.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |